Next-Generation Sequencing in Precision Medicine Market Size is valued at US$ 6.4 Bn in 2024 and is predicted to reach US$ 28.6 Bn by the year 2034 at an 16.4% CAGR during the forecast period for 2025 to 2034.
In the context of precision medicine, "next-generation sequencing" (NGS) refers to advanced DNA and RNA sequencing technologies that provide rapid, accurate, and comprehensive genetic material analysis. NGS may process millions of DNA fragments simultaneously, enabling researchers and clinicians to identify genetic variations, mutations, and biomarkers at a scale and speed never before achievable. NGS enables precision medicine by enhancing diagnosis, forecasting disease risk, and choosing the most effective treatments by tailoring medical interventions to each patient's distinct genomic profile. The market for next-generation sequencing in precision medicine is expected to grow significantly due to its revolutionary effects in providing precise, individualized diagnostics and treatments.
Additionally, the demand for genomic-based therapy customization to an individual's genetic composition is being driven by the rising prevalence of uncommon diseases, cancer, and genetic abnormalities. The industry is expanding more quickly due to the growing use of next-generation sequencing in pharmacogenomics, oncology, and rare illness diagnosis, as well as improved bioinformatics, falling sequencing prices, and supportive government regulations. Moreover, pharmaceutical companies use NGS to create targeted medications and find biomarkers. The next-generation sequencing in the precision medicine market is growing due to regulatory backing for companion diagnostics.
The next-generation sequencing in precision medicine market is segmented by product & service, technology, application, and end-use. By product & service, the market
| minimal residual disease |
is segmented into ngs services, sequencing instruments, consumables & reagents, bioinformatics software, and library preparation kits. By technology, the market is segmented into rna sequencing, whole genome sequencing (wgs), targeted sequencing, whole exome sequencing (wes), and single-cell sequencing. The application segment included infectious disease, rare & inherited disorders, pharmacogenomics, oncology (cancer genomics), prenatal and reproductive health. By end-use, the market is segmented into hospitals & clinics, diagnostic laboratories, biopharmaceutical companies, academic & research institutions, and cros (contract research organizations).
Technology breakthroughs, growing use of high-throughput platforms, and the growing need for customized treatments have all contributed to the sequencing instruments segment's greatest revenue share in the next-generation sequencing in precision medicine market in 2024. The ability to quickly, accurately, and economically sequence DNA and RNA is made possible by these tools, and it is crucial for customizing medical interventions to each patient's unique genetic profile. Additionally, major market participants' ongoing innovation to improve sequencing speed and lower operating costs is supporting the segment's growth.
In 2024, the next-generation sequencing in the precision medicine market was driven by the oncology segment. Since tumors are complicated and heterogeneous, NGS is widely employed in biomarker discovery, tailored treatment, and cancer diagnostics. Demand is further fueled by rising cancer prevalence. Additionally, through tumor profiling, actionable mutation discovery, minimal residual disease (MRD) detection, and continuous resistance evaluation, NGS technology has revolutionized oncology. NGS is being used in oncology pathways at academic institutions, hospitals, and CROs to improve patient care. The convergence of testing standards and reimbursement structures cements the relevance of genomics in contemporary cancer care.
North America held the largest share in the next-generation sequencing in precision medicine market because of the region's technologically advanced healthcare research framework and widespread use of NGS technology in precision medicine. The most advanced healthcare system in North America also comprises biotechnology companies, research hospitals, and esteemed academic institutions. Additionally, strong healthcare infrastructure, government support for precision medicine, and large investments in genomic research all contribute to the expansion of the next-generation sequencing in precision medicine market.
Furthermore, the market for next-generation sequencing in precision medicine in Asia-Pacific is being pushed by rising healthcare spending and the rise in non-communicable diseases (NCDs). Additionally, APAC governments—including those of China, India, and Japan—are actively assisting genomic programs to promote precision medicine. The region also gains from smart partnerships with world leaders, cost-effective manufacturing, and rapid technological advancements by regional firms. The market for next-generation sequencing in precision medicine is growing quickly in Asia due to rising pharmaceutical R&D spending and growing public awareness of genetic testing.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 6.4 Bn |
| Revenue Forecast In 2034 | USD 28.6 Bn |
| Growth Rate CAGR | CAGR of 16.4% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Product & Service , By Technology, By Application, By End-use, and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; Germany; The UK; France; Italy; Spain; Rest of Europe; China; Japan; India; South Korea; Southeast Asia; Rest of Asia Pacific; Brazil; Argentina; Mexico; Rest of Latin America; GCC Countries; South Africa; Rest of the Middle East and Africa |
| Competitive Landscape | Danaher, Thermo Fisher Scientific, Agilent Technologies, Eurofins Scientific, Pacific Biosciences (PacBio), Oxford Nanopore Technologies, Takara Bio, BGI Group (MGI Tech), QIAGEN, Illumina, Roche, Merck KgaA, BD (Becton, Dickinson and Company), 10x Genomics, New England Biolabs, Zymo Research, Novogene, Promega Corporation, Revvity (formerly PerkinElmer), and LGC Limited |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Next-Generation Sequencing in Precision Medicine Market by Product & Service-
Next-Generation Sequencing in Precision Medicine Market by Technology -
Next-Generation Sequencing in Precision Medicine Market by Application-
Next-Generation Sequencing in Precision Medicine Market by End-use-
Next-Generation Sequencing in Precision Medicine Market by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Next-Generation Sequencing in Precision Medicine Market Snapshot
Chapter 4. Global Next-Generation Sequencing in Precision Medicine Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global Next-Generation Sequencing in Precision Medicine Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on NEXT-GENERATION SEQUENCING IN PRECISION MEDICINE MARKET Industry Trends
Chapter 5. Next-Generation Sequencing in Precision Medicine Market Segmentation 1: By Technology, Estimates & Trend Analysis
5.1. Market Share by Technology, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Technology:
5.2.1. Whole Genome Sequencing (WGS)
5.2.2. Whole Exome Sequencing (WES)
5.2.3. Targeted Sequencing
5.2.4. RNA Sequencing
5.2.5. Single-Cell Sequencing
Chapter 6. Next-Generation Sequencing in Precision Medicine Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
6.2.1. Oncology (Cancer Genomics)
6.2.2. Infectious Disease
6.2.3. Rare & Inherited Disorders
6.2.4. Prenatal and Reproductive Health
6.2.5. Pharmacogenomics
Chapter 7. Next-Generation Sequencing in Precision Medicine Market Segmentation 3: By Product & Service, Estimates & Trend Analysis
7.1. Market Share by Product & Service, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product & Service:
7.2.1. Sequencing Instruments
7.2.2. Consumables & Reagents
7.2.3. Library Preparation Kits
7.2.4. Bioinformatics Software
7.2.5. NGS Services
Chapter 8. Next-Generation Sequencing in Precision Medicine Market Segmentation 4: By End Use, Estimates & Trend Analysis
8.1. Market Share by End Use, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following End Use:
8.2.1. Hospitals & Clinics
8.2.2. Academic & Research Institutions
8.2.3. Biopharmaceutical Companies
8.2.4. Diagnostic Laboratories
8.2.5. CROs (Contract Research Organizations)
Chapter 9. Next-Generation Sequencing in Precision Medicine Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Next-Generation Sequencing in Precision Medicine Market, Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.2.3. North America Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.2.4. North America Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Product & Service, 2021-2034
9.2.5. North America Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by End Use, 2021-2034
9.3. Europe
9.3.1. Europe Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.3.3. Europe Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.3.4. Europe Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Product & Service, 2021-2034
9.3.5. Europe Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by End Use, 2021-2034
9.4. Asia Pacific
9.4.1. Asia Pacific Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.4.3. Asia Pacific Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.4.4. Asia Pacific Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Product & Service, 2021-2034
9.4.5. Asia Pacific Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by End Use, 2021-2034
9.5. Latin America
9.5.1. Latin America Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.5.3. Latin America Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.5.4. Latin America Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Product & Service, 2021-2034
9.5.5. Latin America Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by End Use, 2021-2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.6.3. Middle East & Africa Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.6.4. Middle East & Africa Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by Product & Service, 2021-2034
9.6.5. Middle East & Africa Next-Generation Sequencing in Precision Medicine Market Revenue (US$ Million) Estimates and Forecasts by End Use, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Illumina
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Thermo Fisher Scientific
10.2.3. Roche
10.2.4. Danaher
10.2.5. QIAGEN
10.2.6. Agilent Technologies
10.2.7. Eurofins Scientific
10.2.8. Pacific Biosciences (PacBio)
10.2.9. Oxford Nanopore Technologies
10.2.10. Takara Bio
10.2.11. BGI Group (MGI Tech)
10.2.12. Merck KGaA
10.2.13. BD (Becton, Dickinson and Company)
10.2.14. 10x Genomics
10.2.15. New England Biolabs
10.2.16. Promega Corporation
10.2.17. Revvity (formerly PerkinElmer)
10.2.18. Zymo Research
10.2.19. Novogene
10.2.20. LGC Limited